BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions Read more →
Chutes & Ladders—Former FDA leader takes new biotech Turn Read more →
Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both Read more →
